BenevolentAI Investor Conference Presentation Deck
The BenevolentAl business model - leveraging our
technology platform to generate new drug IP at scale
Al-Discovery Tools
Target
Identification
C
соо
D
Precision
Medicine
OO
Knowledge
Graph
Molecular
Design
vuju
100% owned in-house
pipeline of novel
discovery-stage assets
taken to IND
Pharma Collaborations:
Selective platform collaborations which
can leverage the Platform in areas
outside our core competencies
Non-commercial collaborations
(DNDI, COVID-19)
Economic
benefits
ESG
A
B
Platform
validation
Platform
validation
BenevolentAl develop
in-house
Out-license at IND, end
Phase I or end Phase II
(upfront, milestones,
royalties)
Data generated enriches the
Benevolent Platform™
Data generated enriches the
Benevolent Platform™
Benevolent 10View entire presentation